Kezar Life Sciences Inc
$ 6.70
-0.89%
26 Feb - close price
- Market Cap 49,504,500 USD
- Current Price $ 6.70
- High / Low $ 6.83 / 6.65
- Stock P/E N/A
- Book Value 11.33
- EPS -8.44
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.31 %
- ROE -0.57 %
- 52 Week High 6.86
- 52 Week Low 3.53
About
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, is dedicated to the discovery and development of new small molecule therapies to address the unmet needs in immune-mediated diseases and cancer in the United States. The company is headquartered in South San Francisco, California.
Analyst Target Price
$6.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-13 | 2025-06-18 | 2025-03-12 | 2024-11-13 | 2024-08-13 | 2024-05-09 | 2024-03-14 | 2023-11-13 | 2023-08-10 | 2023-05-11 | 2023-03-14 |
| Reported EPS | -1.53 | -1.87 | -2 | -3 | -2.78 | -0.27 | -0.3 | -0.44 | -0.32 | -0.34 | -0.31 | -0.25 |
| Estimated EPS | -0.26 | -0.28 | -2.65 | -2.76 | -3.15 | -0.32 | -0.33 | -0.38 | -0.35 | -0.32 | -0.29 | -0.28 |
| Surprise | -1.27 | -1.59 | 0.65 | -0.24 | 0.37 | 0.05 | 0.03 | -0.06 | 0.03 | -0.02 | -0.02 | 0.03 |
| Surprise Percentage | -488.4615% | -567.8571% | 24.5283% | -8.6957% | 11.746% | 15.625% | 9.0909% | -15.7895% | 8.5714% | -6.25% | -6.8966% | 10.7143% |
Next Quarterly Earnings
| Feb 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KZR
2026-01-09 10:37:31
Kezar Life Sciences announced that the FDA has granted them a Type C meeting in Q1 to discuss the development of zetomipzomib for autoimmune hepatitis (AIH). The meeting will review a potential global Phase 2b clinical study, supported by new pharmacokinetic and safety data aimed at modifying previous patient monitoring requirements. This collaboration with the FDA is intended to clarify the development pathway for zetomipzomib and maximize shareholder value during Kezar's ongoing strategic review.
2026-01-09 10:37:31
Kezar Life Sciences (KZR) announced that the FDA Division of Hepatology and Nutrition has granted them a Type C meeting for the first quarter to discuss the development of zetomipzomib for autoimmune hepatitis. This meeting will focus on a potential global, randomized Phase 2b clinical study. The company believes that further safety and pharmacokinetic data support zetomipzomib's potential to significantly impact the treatment of this serious disease, and alignment with the FDA on trial conduct will provide a clear development pathway.
2026-01-09 10:37:31
Kezar Life Sciences (KZR) has been granted a Type C meeting with the FDA for the first quarter of 2026 to discuss the development of zetomipzomib for autoimmune hepatitis (AIH). The meeting will focus on a potential global, randomized Phase 2b clinical study, leveraging previously submitted pharmacokinetic and hepatic safety data to support the trial and an updated risk-mitigation plan. This initiative aims to address a significant unmet medical need in AIH patients and establish a clear development pathway for the novel therapy.
2026-01-09 06:01:00
Kezar Life Sciences announced that the FDA has granted them a Type C meeting for the first quarter to discuss the development of zetomipzomib for autoimmune hepatitis (AIH). The meeting will cover a potential global Phase 2b clinical study and aims to align with the FDA on critical trial parameters, potentially leading to a clear development pathway for the treatment. Additionally, Kezar has submitted further safety and pharmacokinetic data to modify the prior FDA requirement for 48-hour in-unit patient monitoring in future AIH studies.
2025-11-23 09:08:54
Kezar Life Sciences (NASDAQ: KZR) presented positive Phase 2a PORTOLA clinical trial data for zetomipzomib in autoimmune hepatitis (AIH) at The Liver Meeting 2025. The data showed 36% of steroid-dependent AIH patients achieved biochemical remission and were able to reduce steroid doses to ≤ 5 mg/day, compared to 0% in the placebo group, with zetomipzomib being generally well-tolerated. Additionally, the company announced preliminary efficacy and safety data from its PALIZADE Phase 2b clinical trial in lupus nephritis (LN), demonstrating favorable outcomes and a consistent safety profile.
2025-11-17 04:22:59
Kezar Life Sciences reported its third-quarter 2025 financial results, highlighting a net loss of $11.2 million and a decrease in R&D and G&A expenses. The company has initiated a strategic review due to an inability to align with the FDA on a registrational trial for zetomipzomib, leading to significant cost-containment measures including a 70% workforce reduction. Cash, cash equivalents, and marketable securities totaled $90.2 million as of September 30, 2025.
